首页> 外文期刊>Clinical proteomics. >Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases
【24h】

Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases

机译:原发性乳腺肿瘤与同步淋巴结转移或异步远处转移之间糖蛋白表达的变化

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Breast cancer is a very heterogeneous disease and some patients are cured by the surgical removal of the primary tumour whilst other patients suffer from metastasis and spreading of the disease, despite adjuvant therapy. A number of prognostic and treatment predictive factors have been identified such as tumour size, oestrogen (ER) and progesterone (PgR) receptor status, human epidermal growth factor receptor type 2 (HER2) status, histological grade, Ki67 and age. Lymph node involvement is also assessed during surgery to determine if the tumour has spread which requires dissection of the axilla and adjuvant treatment. The prognostic and treatment predictive factors assessing the nature of the tumour are all routinely based on the status of the primary tumour. Results: We have analysed a unique tumour set of fourteen primary breast cancer tumours with matched synchronous axillary lymph node metastases and a set of nine primary tumours with, later developed, matched distant metastases from different sites in the body. We used a pairwise tumour analysis (from the same individual) since the difference between the same tumour-type in different patients was greater. Glycopeptide capture was used in this study to selectively isolate and quantify N-linked glycopeptides from tumours mixtures and the captured glycopeptides were subjected to label-free quantitative tandem mass spectrometry analysis. Differentially expressed proteins between primary tumours and matched lymph node metastasis and distant metastasis were identified. Two of the top hits, ATPIF1 and tubulin (3-chain were validated by immunohistochemistry to be differentially regulated.
机译:背景:乳腺癌是一种非常不同的疾病,尽管有辅助治疗,但一些患者可通过手术切除原发肿瘤而治愈,而其他患者则患有该疾病的转移和扩散。已经确定了许多预后和治疗预测因素,例如肿瘤大小,雌激素(ER)和孕激素(PgR)受体状态,人类表皮生长因子受体2型(HER2)状态,组织学等级,Ki67和年龄。手术期间还评估了淋巴结受累情况,以确定肿瘤是否扩散,这需要解剖腋窝并进行辅助治疗。评估肿瘤性质的预后和治疗预测因素通常都是基于原发肿瘤的状态。结果:我们分析了一组独特的肿瘤,包括十四个原发性乳腺癌肿瘤,具有相匹配的同步腋窝淋巴结转移,以及一组九个原发性肿瘤,这些肿瘤后来从体内不同部位发生了匹配的远处转移。我们使用成对肿瘤分析(来自同一个体),因为不同患者中相同肿瘤类型之间的差异更大。在这项研究中使用糖肽捕获来从肿瘤混合物中选择性分离和定量N-连接的糖肽,并对捕获的糖肽进行无标记的定量串联质谱分析。确定了原发肿瘤与匹配的淋巴结转移和远处转移之间差异表达的蛋白质。免疫组化验证了两个热门命中的ATPIF1和微管蛋白(3链)的差异性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号